STAT+: European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval

A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely to win approval there, the company announced Wednesday.

Aduhelm received a “negative trend vote” from experts at the European Medicines Agency, following a type of hearing called an oral explanation.

Continue to STAT+ to read the full story…